Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium ...Middle East

Company plans to host a conference call on October 13, 2023 CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today...

Hence then, the article about nuvalent to present preliminary data from alkove 1 phase 1 2 clinical trial of nvl 655 at 35th aacr nci eortc symposium was published today ( Monday 18/09/2023 - 01:32 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium )

Also on site :

• Heat Warning Issued as 450,000 Told Stay Inside for 60 Hours in California
• UCSD, San Diego State part of widespread attack on Canvas education platform
• Sacramento State caught in nationwide cyberattack targeting online learning platform